Saturday, May 25, 2024

Localized Prostate Cancer Survival Rate

Must read

What Is Localised Prostate Cancer

Localized Prostate Cancer: Active Surveillance – 2021 Prostate Cancer Patient Conference

Localised prostate cancer is cancer thats inside the prostate and hasnt spread to other parts of the body. You may also hear it called early or organ-confined prostate cancer, or stage T1 or T2 prostate cancer.

Most localised prostate cancer grows slowly or doesnt grow at all and has a low risk of spreading. So it may never cause you any problems or affect how long you live. Because of this, localised prostate cancer might not need treatment. You might be able to have your cancer monitored with regular check-ups instead. This is to make sure the cancer isnt growing more quickly than expected.

But some men will have cancer that grows quickly and has a high risk of spreading. This is more likely to cause problems and needs treatment to stop it spreading outside the prostate.

Treatments To Control And Prevent Symptoms Caused By The Spread Of Prostate Cancer To The Bones

Palliative External beam radiotherapy

Radiopharmaceuticals: Strontium-89 , samarium-153

Radium-223 dichloride is now licensed and called Xofigo. This is not widely available in the UK but BPC is one of a relatively small number of specialist centres using this treatment.

Zolidronic acid a bisphosphonate given by a 15 minute intravenous infusion every 34 weeks. It reduces the risk of bone complications, including pain and fractures.

Xgeva : this is a newly licensed drug available at BPC.

Pain medications

Surgery may be undertaken to treat bone fractures or to relief the pressure on the spinal cord by bone metastases.

Read Also: Stage 4 Prostate Cancer Spread To Liver Life Expectancy

What Is The Survival Rate For Prostate Cancer

The average five-year survival rate for prostate cancer is very optimistic: 98%. This means it is relatively unlikely that a man diagnosed with prostate cancer will die from the disease.

This high survival rate is largely attributable to the fact that most prostate cancers are detected before the prostate cancer spreads to other organsin other words, when it is localized. Prostate cancer is detected at these earlier stages with regular screenings, which is why its so important for men to begin screening for prostate cancer at age 50.

That being said, there are aggressive prostate cancers that may decrease the chance of survival. The chances of survival dramatically decrease if the cancer has the opportunity to spread to further areas of the body.

Also Check: How To Stimulate A Man’s Prostate

Survival Rates For Prostate Cancer

Survival rates can give you an idea of what percentage of people with the same type and stage of cancer are still alive a certain amount of time after they were diagnosed. These rates cant tell you how long you will live, but they may help give you a better understanding of how likely it is that your treatment will be successful.

Keep in mind that survival rates are estimates and are often based on previous outcomes of large numbers of people who had a specific cancer, but they cant predict what will happen in any particular persons case. These statistics can be confusing and may lead you to have more questions. Ask your doctor, who is familiar with your situation, how these numbers may apply to you.

Survival By Disease Progression

ASCO GU 2020: Optimal Integration of Systemic and Localized Treatment ...

The extent prostate cancer has progressed can influence survival rates.

Prostate-specific antigen is a protein produced by cells of the prostate gland by normal and malignant cells. In men with prostate cancer, blood levels of PSA are often elevated.

Doctors can use PSA as a marker to better understand the progression of prostate cancer and the resulting prognosis.

One way doctors assess the progression of the disease is through PSA doubling time. This refers to the number of months it takes for PSA to double.

One study suggests a short doubling time means a poorer prognosis for patients with stage IV prostate cancer. Median survival was 16.5 months for those with a PSA doubling time lower than 45 days compared with 26 months for patients with a longer PSA doubling time.

Whether or not the cancer has metastasized and spread to other areas of the body outside the prostate can also influence survival. In distant or stage IV prostate cancer, when cancer has spread from the prostate to other organs like the liver or lungs, the five-year survival rate is 31% compared with localized cancer, which has a five-year survival rate of nearly 100%.

You May Like: Metastatic Hormone Sensitive Prostate Cancer

What Is A 5

A relative survival rate compares people with the same type and stage of cancer to people in the overall population. For example, if the 5-year relative survival rate for a specific stage of prostate cancer is 90%, it means that men who have that cancer are, on average, about 90% as likely as men who dont have that cancer to live for at least 5 years after being diagnosed.

Handling Of Missing Data

A substantial proportion of cases had at least one or more of the key clinical prognostic variables missing. We performed multiple imputations using all other covariates to predict values for these variables. We constructed five imputed datasets, each having estimates for the missing values for PSA, Gleason score, and T-stage. We then pooled the estimates and corresponding SEs across the five imputations using Rubin’s method. All model results used these imputed datasets multivariate models using only the complete cases did not show any significant deviations from the results shown.

You May Like: What Does The Prostate Gland Do During Ejaculation

The Initial Causes Stage 3 Prostate Cancer Survival Rate

One of the first symptoms of prostate issues is pain or tenderness in the groin or lower back. This can be the result of a noncancerous condition called enlarged prostatic tissue, or it could be an infection of the bladder. In either case, its important to see a doctor as soon as possible. If youre suffering from prostate pain, you may want to consider reducing your caffeine intake.

Another symptom of a potentially enlarged prostate is difficulty starting a stream of urine, leaking, or dribbling. These symptoms are not serious, but theyre still alarming. Most men put up with an enlarged prostate for years before seeking medical attention, but they typically seek treatment as soon as they notice symptoms. Even if you dont have symptoms, its worth getting checked to determine if you have any prostate issues.

If you experience nightly bathroom runs, you may be experiencing an enlarged prostate. You may be having difficulty starting a stream of urine, or you may even be dribbling or leaking during the day. These problems arent life-threatening, but can become a nuisance. You should not ignore these signs and seek treatment as soon as you notice them. If you feel any of these symptoms, you should consult a doctor.

How Do Doctors Determine Survival Rates

Localized Prostate Cancer: Radiation – 2021 Prostate Cancer Patient Conference

The National Cancer Institute studies and documents five-year survival rates in cancer patients. This information is gathered in the SEER database.

SEER does not study cancers based on their stages, but on the degree that they have spread. The categories of survival rates in SEER include:

  • Localized: The cancer has not spread outside of the organ.
  • Regional: The cancer has spread to nearby areas.
  • Distant: The cancer has spread to other, farther areas of the body.

Doctors utilize this information to determine and share information regarding survival rates for cancer. Again, this is not predictive, only an average, and your experience may be different.

Recommended Reading: How To Reduce Prostate Inflammation

Psa Doubling Time Following Primary Therapy

We estimated the PSA trajectory by calculating the PSA doubling time 21 22 from the time of nadir after radiotherapy or undetectable PSA after prostatectomy to 1) the first SADT use, or 2) to the end of follow-up for patients without SADT use. The PSA doubling time was the natural log of 2 divided by the slope of a linear regression of the log over time. The PSA slope was estimated with the use of linear least squares when three or more PSA values were available, or by calculation using the formula log PSA 1 when only two PSA values were available, where PSA1 and PSA2 were obtained at times T1 and T2, respectively.21 The PSA doubling time was finally categorized into 4 levels : < 9.0, 9.0-< 15.0, 15.0-< 36.0, and â¥36.0 in multivariate analysis.17 29

Enzalutamide Improves Survival In Patients With Metastatic Prostate Cancer


In an international randomizedphase III clinical trial, the hormone therapy enzalutamide extended survival in men with metastatic prostate cancer that had progressed during treatment with androgen deprivation therapy. Participants in the trial had not received chemotherapy.

New England Journal of Medicine, June 1, 2014.


Early in their development, prostate cancers need relatively high levels of male sex hormones to grow. The testes are the main source of androgens, and treatments that stop the testes from producing male sex hormonesknown as hormone therapy or androgen deprivation therapy are therefore a common treatment for androgen-sensitive prostate cancer. However, most prostate cancers eventually become castrate resistantthat is, they can grow even when androgen levels in the blood are very low. ADT does not block production of the small amount of androgen that is made by the adrenal glands and by prostate cancer cells themselves, and this low level is sufficient to fuel the growth of castrate-resistant prostate cancers.

Enzalutamide is among several hormone therapies that have been developed to prevent the androgen-fueled growth of castrate-resistant prostate cancers. This drug works by keeping androgens from binding to the androgen receptors on prostate cancer cells.

The Study

Men in the trial were randomly assigned to receive 160 mg of enzalutamide or a placebo taken orally once daily.


  • Posted:June 27, 2014

Don’t Miss: What Kind Of Doctor Checks For Prostate Cancer

Survival Analyses After Propensity Score Matching

Based on the propensity matched cohorts of 879 chemotherapy-exposed vs 1611 chemotherapy-naïve patients, overall survival rates at 18 and 30 months were 76.3 vs 70.5% and 61.6 vs 56.0%, favoring chemotherapy-exposed patients .

In multivariable Cox regression models, chemotherapy exposed patients exhibited lower overall mortality compared to chemotherapy naïve patients . The effect of better survival in chemotherapy-exposed remained unchanged after landmark analyses was applied in the propensity score matched cohort .

Table 2 Multivariable Cox regression models predicting overall mortality in de novo metastatic prostate cancer patients according to chemotherapy status prior to and after propensity score matching.

Recommended Reading: What Helps With Prostate Cancer

How We Treat Prostate Cancer

(PDF) Impact of Comorbidity on Survival Among Men With Localized ...

The prognosis for metastatic prostate cancer can be discouraging, but some treatment centerslike the Johns Hopkins Precision Medicine Center of Excellence for Prostate Cancerspecialize in innovative, individualized therapy with the potential to improve outcomes.

Read Also: Is Cayenne Pepper Good For Your Prostate

Do You See A Urologist For Prostate Cancer

Often, if a physician suspects their patient has prostate cancer, they will refer them to a urologist for further evaluation. Urologists specialize in diagnosing and treating diseases of the urinary system, including prostate cancer. A urologist can conduct a biopsy to confirm a prostate cancer diagnosis. During the biopsy, a thin, hollow needle will be inserted into the prostate to collect a sample of prostate tissue. The needle may be inserted multiple times to collect several samples.

Within a few days, the urologist should have the diagnosis. If the biopsy is positive for prostate cancer, he or she will then stage the cancer and discuss the patients treatment options. Some patients with early-stage prostate cancer may be eligible for an active surveillance approach in which their condition will be monitored regularly. Treatment may be considered if the cancer begins to spread or cause symptoms.

Watchful Waiting Or Active Surveillance/active Monitoring

Asymptomatic patients of advanced age or with concomitant illness may warrantconsideration of careful observation without immediate active treatment. Watch and wait, observation, expectant management, and active surveillance/active monitoring are terms indicating a strategy that does not employ immediate therapy with curative intent.

Watchful waiting and active surveillance/active monitoring are the most commonly used terms, and the literature does not always clearly distinguish them, making the interpretation of results difficult. The general concept of watchful waiting is patient follow-up with the application of palliative care as needed to alleviate symptoms of tumor progression. There is no planned attempt at curative therapy at any point in follow-up. For example, transurethral resection of the prostate or hormonal therapy may be used to alleviate tumor-related urethral obstruction should there be local tumor growth hormonal therapy or bone radiation might be used to alleviate pain from metastases. Radical prostatectomy has been compared with watchful waiting or active surveillance/active monitoring in men with early-stage disease .

  • Regular patient visits.
  • Transrectal ultrasound .
  • Transrectal needle biopsies .

Patient selection, testing intervals, and specific tests, as well as criteria for intervention, are arbitrary and not established in controlled trials.

You May Like: Aneros Helix Trident Prostate Massager

What Will This Summary Tell Me

This summary will tell you about:

  • What localized prostate cancer is
  • Common treatment options for localized prostate cancer
  • What researchers found about how the treatments compare
  • Possible side effects of the treatments
  • Things to talk about with your doctor

This summary does not cover:

  • How to prevent prostate cancer
  • Less common treatments for localized prostate cancer, such as high-intensity focused ultrasound , cryotherapy , proton-beam radiation therapy , and stereotactic body radiation therapy
  • Herbal products or vitamins and minerals
  • Treatments for cancer that has spread outside the prostate gland

*In this summary, the term doctor refers to your health care professional, including your primary care physician, urologist, oncologist, nurse practitioner, or physician assistant.

Prostate Cancer Survival Rates: What They Mean

Current Mortality Rates on Prostate Cancer Patients

As cancer diagnoses go, prostate cancer is often a less serious one. Prostate cancer is frequently slow-growing and slow to spread. For many men, prostate cancer is less serious than their other medical conditions.

For these reasons, and possibly because of earlier detection of low-grade prostate cancers, prostate cancer has one of the highest survival rates of any type of cancer. WebMD takes a look at prostate cancer survival rates and what they mean to you.

You May Like: How Do You Stop Incontinence After Prostate Surgery

Good Prostate Cancer Care

Your MDT will be able to recommend what they feel are the best treatment options, but ultimately the decision is yours.

You should be able to talk with a named specialist nurse about treatment options and possible side effects to help you make a decision.

You should also be told about any clinical trials you may be eligible for.

If you have side effects from treatment, you should be referred to specialist services to help stop or ease these side effects.

Recommended Reading: What Causes The Prostate Gland To Become Enlarged

Radiation Therapy And Radiopharmaceutical Therapy

External-beam radiation therapy

Candidates for definitive radiation therapy must have a confirmed pathologic diagnosis of cancer that is clinically confined to the prostate and/or surrounding tissues . Staging laparotomy and lymph node dissection are not required.

Radiation therapy may be a good option for patients who are considered poor medical candidates for radical prostatectomy. These patients can be treated with an acceptably low complication rate if care is given to the delivery technique.

Long-term results with radiation therapy are dependent on stage and are associated with dosimetry of the radiation.

Evidence :

  • A retrospective review of 999 patients treated with megavoltage radiation therapy showed that cause-specific survival rates at 10 years varied substantially by T stage: T1 , T2 , T3 , and T4 . An initial serum PSA level higher than 15 ng/mL is a predictor of probable failure with conventional radiation therapy.
  • Several randomized studies have demonstrated an improvement in freedom from biochemical recurrence with higher doses of radiation therapy as compared with lower doses . None of the studies demonstrated a cause-specific survival benefit to higher doses.
  • After a median follow-up of 10 years, despite a statistically significant improvement in biochemical PFS with the higher dose of radiation, the 10-year OS rate was the same in both groups: 71% . Likewise, there were no differences in prostatecancer-specific survival.
  • Evidence :


    Read Also: Can Prostate Cancer Spread To The Testicles

    Treatment Option Overview For Prostate Cancer

    In This Section

    Local treatment modalities are associated with prolonged disease-free survival for many patients with localized prostate cancer but are rarely curative in patients with locally extensive tumors. Because of clinical understaging using current diagnostic techniques, even when the cancer appears clinically localized to the prostate gland, some patients develop disseminated tumors after local therapy with surgery or radiation.

    Treatment options for each stage of prostate cancer are presented in Table 6.

    Table 6. Treatment Options by Stage for Prostate Cancer

    Stage Standard Treatment Options
    EBRT = external-beam radiation therapy LH-RH = luteinizing hormone-releasing hormone PARP = poly polymerase TURP = transurethral resection of the prostate.
    Stage I Prostate Cancer
    PARP inhibitors for men with prostate cancer and BRCA1, BRCA2, and/or ATM mutations

    Side effects of each of the treatment approaches are covered in the relevant sections below. Patient-reported adverse effects differ substantially across the options for management of clinically localized disease, with few direct comparisons, and include watchful waiting/active surveillance/active monitoring, radical prostatectomy, and radiation therapy. The differences in adverse effects can play an important role in patient choice among treatment options. Detailed comparisons of these effects have been reported in population-based cohort studies, albeit with relatively short follow-up times of 2 to 3 years.

    Assessing Proportional Hazards Assumption

    Overall survival for patients with or without a PSA bounce (p

    We assessed departures from the proportional hazards assumption by adding a time-varying covariate to the model in the form of the product of the specific variable and a function of time. The proportional hazards assumption for each covariate was tested individually. If the assumption was violated, we performed stratified analysis on that variable to adjust for differences.

    Also Check: Can A Enlarged Prostate Be Reduced

    More articles

    Popular Articles